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PERITUMORAL TISSUE IN PATIENTS DIAGNOSED WITH 
HEPATOCELLULAR CANCER AFTER HCV CURE SHOWS 
STUBBORN B CELLS AND MACROPHAGE ENRICHMENT
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66% of these patients and HCC risk remains elevated. It is 
LPSRUWDQWWRGH¿QHWKHPHFKDQLVPVRISHUVLVWHQWLQÀDPPDWLRQ
DQGWRGHWHUPLQHWKHLUUHODWLRQVKLSWRWXPRULJHQHVLVDIWHU+&9
cure. CXCL13 (also called B cell-attracting chemokine 1) is 
LQYROYHG LQ KHSDWLF %O\PSKRF\WH WUDI¿FNLQJ DQG O\PSKRLG
follicle development. 0HWKRGVLiver samples were obtained 
from 29 HCC patients who underwent liver transplant in Rush 
University Medical Center from 2015 to 2017. Three groups 
ZHUH GH¿QHG +&9 DQWLERG\ $%++&951$- (N=7, cured), 
+&9$%++&951$+ 1  FKURQLF DQG +&9$%- (N=11, 
controls) (Table 1). Immunostaining of non-tumor areas of the 
OLYHU GHOLQHDWHG WKH LQÀDPPDWRU\ LQ¿OWUDWH DQWL&'&'
CD38, CD68); anti-CXCL13 measured B cell recruitment and 
DQWL0'$ LQGLFDWHG UHVSRQVHV WR LQWHUIHURQĮ VWLPXODWLRQ
6WDLQLQJZDVREMHFWLYHO\TXDQWL¿HGE\LQWHJUDWHGGHQVLW\ZLWK
Image J. The Tabula Muris database, which was used to identify 
liver cells that express CXCL13 ÀDJJHG WKH PDFURSKDJH
population. 5HVXOWVThe most striking result was the high 
H[SUHVVLRQRI&;&/LQSDWLHQWVEHIRUHDQGDIWHU+&9FXUH
Expression was similar in patients with chronic infection and 




patients compared to controls. There was a statistically 
VLJQL¿FDQWFRUUHODWLRQU S EHWZHHQ&'VWDLQLQJ
and CXCL13 staining, indicating that hepatic macrophages 
FRQWULEXWH WR% FHOO UHFUXLWPHQW EHIRUH DQGDIWHU+&9FXUH
7KH WZR JURXSV RI +&9H[SRVHG SDWLHQWV DQG WKH FRQWUROV
KDGVLPLODUVWDLQLQJRI&'7DQG1.7FHOOVDQG&'D
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%DFNJURXQG$PLQRULW\RISDWLHQWVIDLOVWRHOLPLQDWH+&9DQG
resistance-associated substitutions (RASs) are commonly 
detected at failure of interferon-free DAA regimens. 0HWKRGV
:LWKLQ WKH ,WDOLDQ QHWZRUN 9,521(7& WKH SUHYDOHQFH RI
NS3/NS5A/NS5B RASs was retrospectively evaluated in 
patients who failed an EASL recommended DAA-regimen 
in 2015-2018. The geno2pheno system and Sorbo MC et 
DO'UXJ5HVLVWDQFH8SGDWHVZHUHXVHGWR LQIHU+&9
genotype/subtype and predict drug resistance. The changes 
in prevalence of RASs over time were evaluated by chi-square 







in 122 pts (32%), 3 in 109 (28%), 1a in 97 (25%), 4 in 37 
 LQ '$$ UHJLPHQVZHUH/'962) LQ
'&962) LQ ' LQ (%5*5=
LQ  9(/62) LQ  */(3,% LQ   DQG
2D in 6 (2%); ribavirin was administered in 123 (32%). The 
NS5A fasta-sequence was available for all patients, NS5B for 
361 (94%), NS3 for 365 (95%). According to the DAA failed 
the prevalence of any RASs was 90%, namely 80/135 (59%) 
in NS3, 313/359 (87%) in NS5A, 114/286 (40%) in NS5B. 
7KHSUHYDOHQFHRIDQ\5$6VVLJQL¿FDQWO\GHFOLQHGIURP
to 2018 (93% vs S 16$5$6V IURP WR
72% (p=0.29), NS3 RASs from 74% to 18% (p<0.001), while 
NS5B RASs remained stable. Independent predictors of any 
5$6VLQFOXGHGDGYDQFHG¿EURVLV$25&,
p=0.004) and genotype (G2 vs G1a AOR 0.03, CI 95% 0.002-
0.31, p=0.004; G3 vs G1a AOR 0.08, CI 95% 0.01-0.62, 
p=0.02; G4 vs G1a AOR 0.05, CI 95% 0.006-0.46, p=0.008), 
DIWHUDGMXVWLQJIRUDJHSUHYLRXV+&9WUHDWPHQWDQG\HDURI
genotype. Notably, full activity was predicted for GLE/PIB in 
RIFDVHVDQGIRUDWOHDVWWZRFRPSRQHQWVRI9(/62)92;
in 53% of cases, no case with full-resistance to either regimen 
was found. &RQFOXVLRQDespite decreasing prevalence over 
the years, RASs remain common at virological failure of DAA 
treatment, particularly in patients with the highest grade of 
OLYHU¿EURVLV7KHLGHQWL¿FDWLRQRI5$6VDIWHUIDLOXUHFRXOGSOD\
a crucial role in optimizing retreatment strategies.
'LVFORVXUHV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